29980 Federal Register / Vol. 66, No. 107 / Monday, June 4, 2001 / Notices

USPA 60/143,134, filed 7/9/99, entitled

‘‘Attenuated human-bovine

chimeric PIV vaccines’’ (now USPA

09/586,479 and PCT/US00/17066,

both filed 6/15/00)

USPA 60/129,006, filed 4/13/99,

entitled ‘‘Production of attenuated

negative stranded RNA virus

vaccines from cloned nucleotides’’

(now PCT/US00/09695, filed 4/12/

00)

USPA 60/170,195, filed 12/10/99,

entitled ‘‘Use of recombinant PIVs

as vectors to protect against

infectious Diseases caused by PIV

and other human Pathogens’’ (now

USPA 09/733,692 and PCT/US00/

33293, both filed 12/8/00)

USPA 60/213,708, filed 6/23/00,

entitled ‘‘RSV vaccines expressing

protective antigens from promoterproximal genes’’

USPA 60/215,809, filed 7/5/00, entitled

‘‘Attenuated human-bovine

chimeric PIV vaccines’’

USPA 60/007,083, filed 9/27/95,

entitled ‘‘Production of infectious

Respiratory Syncytial Virus from

cloned nucleotide sequences’’ (now

USPA 08/720,132 and PCT/US96/

15524, both filed 9/27/96)

The contemplated exclusive license

may be limited to the development of

live, attenuated vaccines for human use

against Respiratory Syncytial Viruses

Types A and B, and Parainfluenza

Viruses Types 1, 2 and 3.

DATES: Only written comments and/or

applications for a license which are

received by the NIH Office of

Technology Transfer on or before

August 3, 2001 will be considered.

ADDRESSES: Requests for a copy of the

patent application, inquiries, comments

and other materials relating to the

contemplated license should be directed

to Uri Reichman, Ph.D., Technology

Licensing Specialist, Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, MD 20852–3804;

Telephone: (301) 496–7056, ext. 240;

Facsimile: (301) 402–0220; E-mail:

reichmau@od.nih.gov. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent application.

SUPPLEMENTARY INFORMATION: The Patent

Applications cover a wide range of

methods to produce live attenuated

vaccines for PIV and RSV. This

includes, for example, deletion or

ablation of non-essential genes (PIV,

USPA 09/350,821), insertion of genes

expressing immune modulatory

molecules (RSV, USPA 60/143,425),

modification of the second translational

open reading frame of the M2 gene

(RSV, USPA 60/143,097), and shifts in

gene positions that modulate expression

of selected genes (RSV, USPA 60/

213,708). It also includes human-bovine

chimeric constructs (PIV, USPA 60/

215,809, USPA 60/143,134; RSV, USPA

60/143,132) or RSV–PIV chimeric

constructs (USPA 60/170,195 for

PIV1,2,3 and USPA 09/291,894 for

RSVA/B). US Provisional Application

60/129,006 relates to a new attenuation

strategy applicable for the development

of RSV and PIV vaccine candidates. It

generally describes the finding that

attenuating mutations identified in

certain negative stranded RNA viruses

are transferable to other viruses of the

Mononegavirale order. US Provisional

Application 60/007,083 describes an

expression system for recovery of RSV

viruses from the corresponding cDNA

sequences.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 60 days from the date of this

published Notice, NIH receives written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: May 25, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 01–13887 Filed 6–1–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Meeting of the Alaska Migratory Bird

Co-management Council

AGENCY: Fish and Wildlife Service,

Interior.

ACTION: Notice of meeting.

SUMMARY: The Alaska Migratory Bird

Co-management Council has scheduled

a public meeting to discuss financial

needs and sources for funding the

operation of the Council and the

regional management bodies.

DATES: The Co-management Council

will meet June 26, 2001.

ADDRESSES: The meeting will be

conducted at the Hawthorn Suites Hotel

at 1110 W. 8th Avenue in Anchorage,

Alaska.

FOR FURTHER INFORMATION CONTACT: For

additional information call Bob Stevens

at 907/786–3499. Individuals with a

disability who may need special

accommodations in order to participate

in the public comment portion of the

meeting should call the above number.

SUPPLEMENTARY INFORMATION: The U.S.

Fish and Wildlife Service formed the

Alaska Migratory Bird Co-Management

Council, which includes Native, State,

and Federal representatives as equals,

by means of a Notice of Decision

published in the Federal Register, 65 FR

16405–16409, March 28, 2000. The

amended Migratory Bird Treaty with

Canada required the formation of such

a management body. The Comanagement Council will make

recommendations for regulations for

spring/summer subsistence harvesting

of migratory birds in Alaska. In addition

the Co-management Council will make

recommendations regarding population

and harvest monitoring, law

enforcement policies, habitat protection,

research and use of traditional

knowledge, and education programs.

The meeting of the Co-management

Council will begin at 8:30 a.m. on

Tuesday, June 26, 2001. The session

will end no later than 5 p.m. that day.

The primary agenda item will be a

discussion of funding alternatives for

the operation of the Co-management

Council and the regional management

bodies that provide recommendations to

the Co-management Council. The public

is invited to attend. The Co-management

Council will provide opportunities for

public comment on agenda items at the

end of the morning session and at the

end of the afternoon session. Additional

opportunities may be provided at the

discretion of the Co-management

Council. Agendas will be available at

the door.

Dated: May 23, 2001.

David B. Allen,

Regional Director, Anchorage, Alaska.

[FR Doc. 01–13936 Filed 6–1–01; 8:45 am]

BILLING CODE 4310–55–P